Berkshire Hathaway's capital injection helped Swiss Re boost its shareholders equity by SFr5.7bn in 2009 to SFr26.2bn.
The Zurich-based giant said it is on schedule to redeem the SFr3bn convertible perpetual capital instrument it issued to the Warren Buffett-headed firm - which, with its quota share, adverse development and retro arrangements, remains Swiss Re's most significant single counterparty risk.
At year-end, Swiss Re's estimated excess capital at AA level was more than SFr 9bn as it returned to profit. The...
You are currently viewing an incomplete version of this article. If you are a subscriber then please login now. If you are a non-subscriber but would like to be able to view this article, then please select from the purchasing options below.